NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-23-119 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases.
Funding Opportunity PAR-23-154 from the NIH Guide for Grants and Contracts. "This FOA would support development and validation of clinically relevant models of AD/ADRD including post-TBI dementias. Models could include small animals, larger animals, ex vivo models, human iPSCs, or other in vitro models. Validation includes internal, face, construct, and predictive (to the extent possible) validation. Such validations could include looking at underlying mechanism/pathways, functional imaging, behavior, and other cognitive readouts. Independent replication is also encouraged. These models can be developed/validated with the goal of supporting therapy development or better understanding of human disease mechanisms and mechanisms that uncover predisposition to developing neurodegenerative dementias. Either way, it is essential that models reflect the human condition as much as possible. Novel models of complex pathology or comorbid conditions are encouraged. Such models could include multiple manipulations (genetics, environment, lifestyle, age, etc.) to better reflect the complex interaction of risk factors in patients. New models need to be innovative and address a gap in the currently available models."
Notice NOT-DA-23-023 from the NIH Guide for Grants and Contracts
Notice NOT-DA-24-007 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-107 from the NIH Guide for Grants and Contracts
Notice NOT-HG-23-035 from the NIH Guide for Grants and Contracts
Notice NOT-HG-23-034 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-157 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This FOA is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)
Funding Opportunity PAR-23-158 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This NOFO is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional).
Funding Opportunity PAR-23-171 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to provide investigators with access to resources provided by the Data Management Coordinating Center for Diagnostic Centers of Excellence (RFA-NS-22-051), as part of the next phase of the Undiagnosed Diseases Network. Resources include infrastructure, data management, and clinical research support for a new Network of clinical sites that provide diagnostic services for patients with undiagnosed diseases.
Notice NOT-AI-23-043 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-23-265 from the NIH Guide for Grants and Contracts. This RFA aims to support the development, testing, validation and implementation of quality metrics in mental health services research, that can be submitted to and endorsed by the relevant regulatory or governing bodies. In order to support the implementation and dissemination of high-quality mental health services, effective measures of defining and assessing quality are needed. Very few measures exist for assessing the quality of mental health care services; as noted by the Agency for Healthcare Research and Quality (AHRQ), these measures are not typically standardized or utilized uniformly. These quality measures can be used by policymakers, payers, organizational leaders, and clinicians for a variety of endeavors, including providing measurement-based care, evaluating the effectiveness of evidence-based care, enacting quality improvement interventions, assessing comparative- and cost-effectiveness across programs or clinical settings, utilizing real-world data in decision-making, and developing payment models, in order to continually improve mental health functioning and outcomes.
Funding Opportunity RFA-AI-23-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote basic research to better understand the mechanisms underlying viral invasion of the central nervous system (CNS), virus- and/or host immune-mediated neuropathogenesis, and the associated clinical manifestations for emerging and re-emerging neurotropic viruses.
Notice NOT-NS-23-083 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DE-24-002 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit developmental/exploratory research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC).
Funding Opportunity RFA-DE-24-001 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC).
Funding Opportunity PAR-23-164 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of, pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research.
Funding Opportunity PAR-23-165 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to FOA PAR XX-XXX .
Notice NOT-DC-23-007 from the NIH Guide for Grants and Contracts
Notice NOT-HS-23-010 from the NIH Guide for Grants and Contracts